Antiviral Drugs revenue Poland 2017-2029

The revenue in the 'Antiviral Drugs' segment of the pharmaceuticals market in Poland was forecast to continuously increase between 2024 and 2029 by in total 10.9 million U.S. dollars (+7.75 percent). According to this forecast, in 2029, the indicator will have increased for the sixth consecutive year to 151.46 million U.S. dollars.

Find more key insights for the revenue in countries and regions like the revenue in the pharmaceuticals market in the United Kingdom and the revenue change in the pharmaceuticals market in Southeast Asia.

The Statista Market Insights cover a broad range of additional markets.

Revenue in the Antiviral Drugs segment in Poland from 2017 to 2029 (in million U.S. dollars)

Characteristic	In million U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

Definition:
The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck

Citation formats